Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized ATG Dosing in Unrelated Allo-HSCT
NCT06572462Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Dec 2020
- Primary completion
- Dec 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of antithymocyte globulin in graft-versus-host disease (GVHD), sponsored by Chinese PLA General Hospital. Primary endpoint: cumulative incidence of CMV reactivation at 180 days. Started Dec 2020; status: recruiting.
02
Drugs
antithymocyte globulin
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06572462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06572462.